688062 Mabwell
- 33.60
- +0.44+1.33%
Mabwell News
Express News | Maiwei Biotech: A clinical trial application for 9MW2821 combined immune checkpoint inhibitors to treat triple-negative breast cancer (TNBC) was accepted
Maiwei Biotech (688062.SH): Net loss of 206 million yuan in the first quarter
Gelonghui, April 29丨Maiwei Biotech (688062.SH) released its report for the first quarter of 2024, achieving operating income of 67.551 million yuan, an increase of 1572.42% over the previous year; net profit attributable to shareholders of listed companies - 206 million yuan, net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss - 218 million yuan, and basic earnings per share of 0.51 yuan.
Guoxin Securities released a research report on April 19 stating that Maiwei Biotech (688062.SH) was rated to increase its holdings. The main reasons for the rating include: 1) rapid growth in product sales; 2) commercialization of core products is progre
Guoxin Securities released a research report on April 19 stating that Maiwei Biotech (688062.SH) was rated to increase its holdings. The main reasons for the rating include: 1) rapid growth in product sales; 2) commercialization of core products is progressing well. (Mainichi Keizai Shimbun)
Maiwei Bio-U (688062): NECTIN-4 ADC multi-indication rapid clinical promotion
Product sales are growing rapidly. Maiwei Biotech achieved revenue of 128 million yuan (+361%) in 2023. The sharp increase in revenue was mainly due to the company's 9MW3011 project's external authorization and receipt of a down payment of 10 million US dollars
Maiwei Biology (688062): Analogs are entering the harvest period and the development of new drugs is being promoted efficiently
Core view: 9MW2821 is progressing smoothly and is the first drug with the same target to disclose CC and EC efficacy data. According to the company's 2023 annual report, 9MW2821 was treated with platinum chemotherapy and anti-PD- (L) 1 treatment
Maiwei Biotech (688062): ADC released multiple data and commercialization of similar drugs in China progressed smoothly
Performance: The company released its annual report on April 9, 2024. The 2023 revenue was 128 million yuan, technical service revenue was 85.5953 million yuan, pharmaceutical sales revenue was 42.09 million yuan, and R&D investment was 8.3 million yuan
Huajin Securities released a research report on April 13 stating that Maiwei Biotech (688062.SH) was given a purchase rating. The main reasons for the rating include: 1) Milesu's marketing contribution; 2) the commercialization of biosimilar drugs is prog
Huajin Securities released a research report on April 13 stating that Maiwei Biotech (688062.SH) was given a purchase rating. The main reasons for the rating include: 1) Milesu's marketing contribution; 2) the commercialization of biosimilar drugs is progressing steadily, and emerging markets continue to be developed; 3) the research pipeline is progressing efficiently, and multiple indications of Nectin-4ADC shows positive curative effects; 4) It has a mature production transformation system and forward-looking layout of large-scale commercial production capacity. (Mainichi Keizai Shimbun)
Maiwei Biotech (688062): Commercialization and capacity construction are steadily advancing, and the NECTIN-4 ADC multi-pipeline is progressing positively
Key investment points Milishu's listing contributed to new volume. The company released its 2023 annual report. (1) In 2023, the company achieved revenue of 128 million yuan (+361.03%, same increase, same below), mainly including technical service revenue of 855 million yuan
Maiwei Bio-U (688062): NECTIN4 ADC shows excellent data in multiple cancer types
Event Overview: The company released its 2023 annual report: The company achieved operating revenue of 12,78355 million yuan, mainly from technical service revenue of 85.5953 million yuan and pharmaceutical sales revenue of 42.0896 million yuan.
SDIC Securities released a research report on April 10 stating that Maiwei Biotech (688062.SH) was given a purchase rating and the target price was 47.95 yuan. The main reasons for the rating include: 1) NECTIN-4 ADC is worth looking forward to; 2) Long-a
SDIC Securities released a research report on April 10 stating that Maiwei Biotech (688062.SH) was given a purchase rating and the target price was 47.95 yuan. The main reasons for the rating include: 1) NECTIN-4 ADC is worth looking forward to; 2) Long-acting whitening agents are expected to be approved for marketing in 2025, and domestic and overseas markets for many biosimilar drugs are being actively expanded. (Mainichi Keizai Shimbun)
Maiwei Biotech (688062.SH) announced its 2023 annual results, with a net loss of 1,053 billion yuan, an increase in losses over the same period last year
Maiwei Biotech (688062.SH) disclosed its 2023 annual report. During the reporting period, the company achieved revenue of 128 million yuan, an increase of 361.03%; net profit loss to mother of 1,053 million yuan, a year-on-year increase; loss of 1.06 billion yuan after deducting non-net profit, a large year-on-year loss; and basic earnings per share of -2.64 yuan.
Mabwell Shanghai Bioscience Unit Gets Nod in China for Denosumab as Bone Tumor Treatment
China's drug regulator approved the marketing application of Mabwell Shanghai Bioscience's (SHA:688062) unit, Jiangsu Taikang Biopharmaceutical, for denosumab, according to a filing with the Shanghai
Express News | Maiwei Biotech: Dexumab injection approved for marketing by the State Drug Administration
Guoxin Securities: The pharmaceutical industry is entering an upward inflection point in the medium to long term, and focus on high growth targets in the quarterly report in the short term
The pharmaceutical industry currently has low growth, low profitability, undervaluation, and low transaction attention, and is entering a major layout range at an upward inflection point in the medium to long term.
Maiwei Biotech (688062) First Coverage Report: Core Product NECTIN-4 ADC Global Progress Leading Product Pipeline Collaborative Promotion at Home and Abroad
The core product Nectin-4 ADC drug is currently in a leading position in clinical progress in the world, and it has potential as a BIC product with the same target ADC drug. Nectin-4 ADC already has Seagen worldwide
Maiwei Biotech showcased IDDC platform technology and ADC drug development results at the 14th World ADC Conference
SHANGHAI, March 19, 2024 /PRNewswire/ -- Miwei Biotech (688062.SH), an innovative biopharmaceutical company with a full industry chain layout, published in the form of a poster at the 14th World ADC Drug Conjugation Conference (World ADC London) from March 12 to 15, 2024, “Mtoxin Payload Applied in IDDC ADC Platform Interventions” Therapeut
Maiwei Biotech is included in the FTSE Russell Global Stock Index
SHANGHAI, March 15, 2024/PRNewswire/ -- Maiwei Biotech (688062.SH), an innovative biopharmaceutical company with a full industrial chain layout, was recently included in the FTSE Global Equity Index Series (FTSE Global Equity Index Series) under the British FTSE Russell Index (FTSE Russell). FTSE Russell is a world-renowned index agency. Its index products cover markets in more than 70 countries and regions around the world, and about 20 trillion US dollars of assets are invested based on FTSE Russell Index products.
A-share changes丨The innovative drug sector rallied in the afternoon, leading the way in AI pharmaceuticals
Gelonghui, March 13 | The innovative drug sector in the A-share market rose in the afternoon, leading in the direction of AI pharmaceuticals. Hongbo Pharmaceutical rose more than 10%, while Chengdu Pioneer, Kain Technology, Zhixiang Jintai, Maiwei Biotech, and Alice followed suit. According to the news, recently, Insilicon Intelligence, one of the unicorns of AI pharmaceuticals in China, published a research paper in the “Nature-Biotech” magazine, revealing the entire process of the TNIK inhibitor developed by the company using artificial intelligence, from target discovery to phase II clinical development, and disclosed for the first time the pre-clinical and clinical trial data of this AI drug.
Maiwei Biotech (688062): Differential Innovation Accelerates NECTIN-4 ADC Leading Global Progress
Established in 2017, Maiwei Biotech is an innovative biopharmaceutical company with a full industrial chain layout. Focusing on the field of multiple diseases, the two products have now been commercialized, and a platform-based enterprise with a full R&D, production and sales industry chain layout has been established. A
Maiwei Biotech will debut at the 14th World ADC Conference
SHANGHAI, March 11, 2024 /PRNewswire/ -- Maiwei Biotech (688062.SH), an innovative biopharmaceutical company with a full industrial chain layout, announced that it will present IDDC, the next-generation ADC technology platform IDDC and multiple ADC varieties developed based on this platform in the form of a poster at the 14th World ADC Drug Coupling Conference (World ADC London) to be held on March 12-15, 2024, local time in London, England 9MW2821 (7MW3711, 9MW2921)
Analysis
Price Target
No Data
